Stock Track | Novo Nordisk Plummets 15.89% Intraday After Obesity Drug Trial Fails to Match Eli Lilly's Treatment

Stock Track02-23 23:49

Novo Nordisk A/S (NVO) shares plummeted 15.89% during Monday's trading session, following a significant pre-market decline. The sharp drop came after the Danish pharmaceutical giant announced disappointing results from a key clinical trial for its next-generation weight-loss drug.

The company reported that its experimental obesity drug, CagriSema, failed to achieve the primary endpoint in the REDEFINE 4 phase 3 trial. The study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly's rival drug tirzepatide in reducing body weight. Patients treated with CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for those taking tirzepatide.

This trial setback represents a significant blow to Novo Nordisk's efforts to maintain competitiveness in the lucrative obesity treatment market, where Eli Lilly's Zepbound (tirzepatide) has been gaining market share. Analysts noted that the inferior performance against the established competitor could limit CagriSema's commercial potential and make it difficult for Novo Nordisk to regain market leadership in obesity treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134200481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134200481","market":"us","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plummets 15.89% Intraday After Obesity Drug Trial Fails to Match Eli Lilly's Treatment","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares plummeted 15.89% during Monday's trading session, following a significant pre-market decline. The sharp drop came after the Danish pharmaceutical giant announced disappointing results from a key clinical trial for its next-generation weight-loss drug.</p><p>The company reported that its experimental obesity drug, CagriSema, failed to achieve the primary endpoint in the REDEFINE 4 phase 3 trial. The study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly's rival drug tirzepatide in reducing body weight. Patients treated with CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for those taking tirzepatide.</p><p>This trial setback represents a significant blow to Novo Nordisk's efforts to maintain competitiveness in the lucrative obesity treatment market, where Eli Lilly's Zepbound (tirzepatide) has been gaining market share. Analysts noted that the inferior performance against the established competitor could limit CagriSema's commercial potential and make it difficult for Novo Nordisk to regain market leadership in obesity treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plummets 15.89% Intraday After Obesity Drug Trial Fails to Match Eli Lilly's Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plummets 15.89% Intraday After Obesity Drug Trial Fails to Match Eli Lilly's Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-23 23:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares plummeted 15.89% during Monday's trading session, following a significant pre-market decline. The sharp drop came after the Danish pharmaceutical giant announced disappointing results from a key clinical trial for its next-generation weight-loss drug.</p><p>The company reported that its experimental obesity drug, CagriSema, failed to achieve the primary endpoint in the REDEFINE 4 phase 3 trial. The study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly's rival drug tirzepatide in reducing body weight. Patients treated with CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for those taking tirzepatide.</p><p>This trial setback represents a significant blow to Novo Nordisk's efforts to maintain competitiveness in the lucrative obesity treatment market, where Eli Lilly's Zepbound (tirzepatide) has been gaining market share. Analysts noted that the inferior performance against the established competitor could limit CagriSema's commercial potential and make it difficult for Novo Nordisk to regain market leadership in obesity treatments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1134200481","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134200481","pubTimestamp":1771861753,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) shares plummeted 15.89% during Monday's trading session, following a significant pre-market decline. The sharp drop came after the Danish pharmaceutical giant announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"股票赛道|肥胖药物试验未能匹配礼来治疗，诺和诺德盘中暴跌15.89%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares plummeted 15.89% during Monday's trading session, following a significant pre-market decline. The sharp drop came after the Danish pharmaceutical giant announced disappointing results from a key clinical trial for its next-generation weight-loss drug.The company reported that its experimental obesity drug, CagriSema, failed to achieve the primary endpoint in the REDEFINE 4 phase 3 trial. The study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly's rival drug tirzepatide in reducing body weight. Patients treated with CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for those taking tirzepatide.This trial setback represents a significant blow to Novo Nordisk's efforts to maintain competitiveness in the lucrative obesity treatment market, where Eli Lilly's Zepbound (tirzepatide) has been gaining market share. Analysts noted that the inferior performance against the established competitor could limit CagriSema's commercial potential and make it difficult for Novo Nordisk to regain market leadership in obesity treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134200481","isCrawlerRequest":true}